PT-141 (Bremelanotide)
All Gender Sexual Arousal
PT-141 (Bremelanotide) is a synthetic peptide that directly enhances sexual desire and arousal by activating melanocortin receptors in the brain. Unlike vascular-targeting therapies such as phosphodiesterase inhibitors (e.g., Viagra), PT-141 bypasses the circulatory system and focuses on central nervous system pathways, making it a groundbreaking treatment for hypoactive sexual desire disorder (HSDD) in women and erectile dysfunction (ED) in men (1, 2, 3). Clinical trials highlight its efficacy, with a 30% success rate in men unresponsive to sildenafil and significant improvement in satisfying sexual experiences for women with HSDD (2, 3). Delivered as a nasal spray, PT-141 offers rapid absorption and ease of use, positioning it as a versatile and innovative therapy for sexual dysfunction and beyond.
*Only the lyophilized product is provided.
All Gender Sexual Arousal
PT-141 (Bremelanotide) is a synthetic peptide that directly enhances sexual desire and arousal by activating melanocortin receptors in the brain. Unlike vascular-targeting therapies such as phosphodiesterase inhibitors (e.g., Viagra), PT-141 bypasses the circulatory system and focuses on central nervous system pathways, making it a groundbreaking treatment for hypoactive sexual desire disorder (HSDD) in women and erectile dysfunction (ED) in men (1, 2, 3). Clinical trials highlight its efficacy, with a 30% success rate in men unresponsive to sildenafil and significant improvement in satisfying sexual experiences for women with HSDD (2, 3). Delivered as a nasal spray, PT-141 offers rapid absorption and ease of use, positioning it as a versatile and innovative therapy for sexual dysfunction and beyond.
*Only the lyophilized product is provided.
All Gender Sexual Arousal
PT-141 (Bremelanotide) is a synthetic peptide that directly enhances sexual desire and arousal by activating melanocortin receptors in the brain. Unlike vascular-targeting therapies such as phosphodiesterase inhibitors (e.g., Viagra), PT-141 bypasses the circulatory system and focuses on central nervous system pathways, making it a groundbreaking treatment for hypoactive sexual desire disorder (HSDD) in women and erectile dysfunction (ED) in men (1, 2, 3). Clinical trials highlight its efficacy, with a 30% success rate in men unresponsive to sildenafil and significant improvement in satisfying sexual experiences for women with HSDD (2, 3). Delivered as a nasal spray, PT-141 offers rapid absorption and ease of use, positioning it as a versatile and innovative therapy for sexual dysfunction and beyond.
*Only the lyophilized product is provided.
Research Insights
1. Sexual Dysfunction
Men: A 30% success rate was observed in achieving erections sufficient for intercourse among men unresponsive to sildenafil (1).
Women: Improved frequency of satisfying sexual experiences and reduced sexual distress scores in premenopausal women with HSDD (2).
2. Combination Therapy Benefits
Enhanced arousal and sustained erectile function when used with phosphodiesterase inhibitors (3).
3. Hemorrhagic Shock
PT-141 reduced ischemic tissue damage and promoted recovery in preclinical models of hemorrhagic shock (4).
4. Immune Modulation
Exhibits anti-inflammatory properties and potential use in fungal infections resistant to current antifungals (4).
5. Cancer Research
Activation of MC1R may influence DNA repair pathways, reducing the risk of basal and squamous cell carcinoma (6).
6. Metabolic and Neurological Applications
Research into melanocortin pathways indicates potential in treating early-onset obesity and metabolic syndrome linked to MC4R mutations (5).
Description & Pharmacodynamics
PT-141 acts primarily through melanocortin-4 receptor (MC4R) and melanocortin-1 receptor (MC1R) activation:
MC4R Activation: Regulates sexual arousal by modulating pathways in the hypothalamus, directly influencing libido and satisfaction (1, 2).
MC1R Activation: Provides systemic effects, including tissue protection during ischemic events and potential roles in immune modulation (4).
Combination Therapy
When combined with phosphodiesterase inhibitors like sildenafil or tadalafil, PT-141 enhances blood flow, improves erectile function, and sustains arousal, particularly for patients with incomplete responses to conventional treatments (3).
Non-Sexual Applications
Hemorrhagic Shock: By activating MC1R and MC4R, PT-141 mitigates ischemic damage and supports tissue recovery in low-oxygen conditions (4).
Immune Modulation: Demonstrates anti-inflammatory properties and potential efficacy against drug-resistant fungal infections (4, 5).
Metabolic Research: Activation of melanocortin pathways highlights its potential in addressing obesity and metabolic syndrome (5).
Structure
Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular Formula: C50H68N14O10
Molecular Weight: 1025.2 g/mol
PubChem CID: 9941679
Citations
Sexual Dysfunction
Rosen, R. C., et al. Evaluation of the effects of subcutaneous PT-141 in male ED patients unresponsive to Viagra.Int. J. Impot. Res., 2004.
Clayton, A. H., et al. Bremelanotide for female sexual dysfunction in premenopausal women. Women’s Health, 2016.
Safarinejad, M. R., & Hosseini, S. Y. Efficacy of Bremelanotide in sildenafil non-responders. J. Urol., 2008.
Immune Modulation and Hemorrhagic Shock
Ji, H., et al. Anti-inflammatory effects of melanocortin analogs. PLOS ONE, 2013.
Metabolic and Neurological Applications
Spana, C., et al. Metabolic and thermogenic implications of melanocortin agonists. Diabetes Obes. Metab., 2022.
Cancer Research
Maresca, V., et al. Skin phototype and implications of melanocortin pathways in cancer. Pigment Cell Melanoma Res., 2015.
